Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/198638
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI) |
Autor: | Capdevila, Jaume; Galofré, J. C.; Grande, Enrique; Zafón Llopis, C.; Ramón y Cajal Asensio, T.; Navarro González, Elena CSIC ORCID; Jiménez-Fonseca, Paula; Santamaría Sandi, J.; Gómez Sáez, J. M.; Riesco-Eizaguirre, Garcilaso CSIC ORCID | Palabras clave: | Differentiated thyroid cancer Lenvatinib Radioactive iodine-refractory thyroid cancer Review Sorafenib Targeted therapy Thyroid cancer |
Fecha de publicación: | mar-2017 | Editor: | Springer Nature | Citación: | Clinical and Translational Oncology 19(3): 279-287 (2017) | Resumen: | Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %. Over the last decade, substantial progress has been made in the management of RAI-refractory DTC. Given the controversy in some areas, the Spanish Task Force for Thyroid Cancer on behalf of Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and the Spanish Rare Cancer Working Group (GETHI) have created a national joint task force to reach a consensus addressing the most challenging aspects of management in these patients. In this way, multidisciplinary management should be mandatory and nuclear medicine targeted therapy, novel molecular targeted agents, and combinations are currently changing the natural history of RAI-refractory DTC. | Versión del editor: | http://dx.doi.org/10.1007/s12094-016-1554-5 | URI: | http://hdl.handle.net/10261/198638 | DOI: | 10.1007/s12094-016-1554-5 | Identificadores: | doi: 10.1007/s12094-016-1554-5 issn: 1699-048X e-issn: 1699-3055 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
26
checked on 16-feb-2023
WEB OF SCIENCETM
Citations
27
checked on 26-mar-2023
Page view(s)
163
checked on 24-abr-2024
Download(s)
17
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.